Systemic lupus erythematosus (SLE) ...........

Systemic lupus erythematosus (SLE) therapy had been a major challenge for many pharmaceutical companies and research institutes not only in Unites states but also in India, According to WHO reports around 5 million people are affected world wide. At present steroids and some immunosuppressant are used for first line of treatment and some companies are targeting for protein based products too, Some of the companies working in this segment includes BioMarin and Roche and partner Biogen Idec, last month at one end news was that La Jolla pharmaceutical was forced to liquidate this august as its key lupus drug Riquent which was in Phase III failed in the key trial....and today the good news is that US based Human Genome Sciences (HGS) with is collaborator GSK has successfully developed lupus drug BLISS-76 which in combination with other drug had shown good results in Phase III trial....It is said that BLISS-76 will be first of its kind in this therapy segment.......